3D-Porous Hybrid Anti-Inflammatory Nanoscaffold for Drug Delivery and Tissue Engineering
US-2021015975-A1 · Jan 21, 2021 · US
US12533445B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12533445-B2 |
| Application number | US-202217664792-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 24, 2022 |
| Priority date | May 24, 2021 |
| Publication date | Jan 27, 2026 |
| Grant date | Jan 27, 2026 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A three dimensional scaffold for generating cell or protein assemblies. This degradable scaffold can be applied to various types of cells. Also disclosed are methods of treating a condition by implanting the protein or cell assembly prepared according to the method described herein.
Opening claim text (preview).
The invention claimed is: 1 . A biodegradable nano porous (BNP) membrane scaffold for forming a protein or a cell assembly, comprising a plurality of nanosheet layers consisting of ultrasonicated porous manganese dioxide (MnO 2 ) particles having an average diameter ranging from about 200 nm to about 100 μm, wherein (i) the scaffold comprises pores with an average diameter ranging from about 1 μm to about 50 μm; and (ii) the particles comprise a plurality of nanosheets, wherein the nanosheets have an average lateral size ranging from about 1 nm to 1 μm, and wherein the nanosheets are assembled in random directions in the particles to form porous channels. 2 . The scaffold of claim 1 , wherein the particles are degradable by a reducing agent. 3 . The scaffold of claim 1 , wherein the particles degrade at a rate of greater than about 10 mg/s under 1 mg/ml vitamin C buffered solution. 4 . The scaffold of claim 1 , wherein the particles comprise MnO 2 doped with a dopant selected from the group consisting of zinc, lithium, iron, and any combination thereof. 5 . The scaffold of claim 1 , further comprising a first group of one or more removable masks covering a first portion of the first surface of the scaffold. 6 . The scaffold of claim 5 , further comprising a second group of one or more removable masks covering a second portion of the first surface, wherein the second group are separate from or overlap with the first group. 7 . The scaffold of claim 5 , wherein the masks comprise a polymer. 8 . The scaffold of claim 5 , wherein an unmasked area on the first surface is patterned to the shape of a tissue. 9 . A method of forming a protein and/or a cell assembly or a hybrid thereof, comprising: (a) depositing a protein and/or a first group of cells on a first surface of the scaffold of claim 1 ; and (b) applying vacuum (negative pressure) to a second surface opposite to the first surface of the scaffold. 10 . The method of claim 9 , wherein the scaffold comprises one or more groups of removable masks covering one or more portions of the first surface of the scaffold, wherein the method further comprises removing a first group of the one or more groups of the masks and depositing a second group of cells to the first surface of the scaffolds. 11 . The method of claim 10 , further comprising removing a second group of the one or more groups of the masks and depositing a third group of cells to the first surface of the scaffold. 12 . The method of claim 9 , wherein the scaffold comprises one or more groups of removable masks covering one or more portions of the first surface of the scaffold, wherein the protein is first deposited to the first surface of the scaffold, and wherein the method further comprises removing a first group of the one or more groups of the masks prior to depositing the first group of cells to the first surface of the scaffolds. 13 . The method of claim 9 , further comprising treating the scaffold with a reducing agent to separate the protein and/or the cell assembly or the hybrid thereof from the scaffold. 14 . The method of claim 9 , wherein the cell assembly has a cell density of over 10 6 cells/cm 2 . 15 . A method of treating a condition in a subject, comprising implanting to the subject in need thereof the protein and/or the cell assembly or the hybrid thereof produced according to claim 9 . 16 . The method of claim 15 , wherein the condition is an open wound.
Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces · CPC title
Macromolecular materials · CPC title
Other specific inorganic materials not covered by A61L27/04 - A61L27/12 · CPC title
Porous materials, {e.g. foams or sponges} · CPC title
Methods for forming porous structures using a negative form which is filled and then removed by pyrolysis or dissolution · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.